Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103+ IL-12-producing dendritic cells and priming CD8+ T cells without involving draining lymph nodes
Open Access
- 10 December 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (12) , e009683
Abstract
Background: Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19). However, the preparation of syngeneic/autologous MSC from individual hosts limits the clinical application of this cell therapy. Methods: In this study, we further developed a new cell therapy using allogeneic iMSC/CCL19 (allo-iMSC/CCL19) using several tumor mice models. Results: The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which the host’s T cells were induced to respond to allogeneic MSC. In addition, the allo-iMSC/CCL19 therapy promoted the infiltration of CD103+ interleukin (IL)-12-producing DCs and priming of CD8+ T cells at tumor sites compared with that using syn-iMSC/CCL19. The antitumor effect of allo-iMSC/CCL19 therapy was not influenced by fingolimod, a sphingosine 1-phosphate receptor modulator, implying no involvement of draining lymph nodes in the priming of tumor-specific T cells. Conclusion: These results suggest that allo-iMSC/CCL19 therapy exerts dramatic antitumor effects by promoting the infiltration of CD103+ IL-12-producing DCs and thereby priming tumor-specific CD8+ T cells at tumor sites. This local cell therapy could be a promising approach to anticancer therapy, particularly for overcoming dysfunction in the cancer-immunity cycle.Keywords
Funding Information
- Japan Society for the Promotion of Science (23K06636)
This publication has 31 references indexed in Scilit:
- The cancer-immunity cycle: Indication, genotype, and immunotypeImmunity, 2023
- CD8+ T cells in the cancer-immunity cycleImmunity, 2023
- Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent miceInternational Immunopharmacology, 2015
- Antitumor Efficacy of CC Motif Chemokine Ligand 19 in Colorectal CancerDigestive Diseases and Sciences, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune systemCytokine & Growth Factor Reviews, 2013
- Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell TransplantationStem Cells, 2013
- Activated Local Immunity by CC Chemokine Ligand 19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian CancerStem Cells, 2009
- Retroviral vector‐producing mesenchymal stem cells for targeted suicide cancer gene therapyThe Journal of Gene Medicine, 2009
- Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapyCancer Immunology, Immunotherapy, 2002